Redsense Medical

Redsense Medical AB (publ) has scheduled its Annual General Meeting (AGM) for May 28, 2025, at Profilhotels Halmstad Plaza. Shareholders must be registered by May 20, 2025, and notify their attendance by May 22, 2025. The meeting will cover several resolutions, including the adoption of annual accounts, board elections, and remuneration. The Nomination Committee proposes Susanne Olauson as Chairman and suggests re-electing certain board members while electing new ones, Mike Griffiths and Johannes Köpple. The company also plans to introduce a performance-based employee stock option program (LTI 2025) for certain employees and consultants, with specific performance targets and vesting conditions. Additionally, the board seeks authorization to issue shares and proposes entering into swap agreements to facilitate LTI 2025. Documents related to the AGM will be available on the company's website and at the company's office.

Redsense Medical AB (publ) har idag publicerat sin årsredovisning för 2024. Denna finns tillgänglig via företagets hemsida och är bifogad i pressmeddelandet. För mer information kan man kontakta VD Sebastien Bollue via telefon eller e-post.

Redsense Medical AB held an Extraordinary General Meeting on April 24, 2025, where all proposed resolutions were approved. The meeting was called because the company did not have a quorate Board of Directors due to unforeseen events earlier in the year. The Nomination Committee plans to propose a new permanent Board of Directors at the Annual General Meeting in late May 2025. Until then, the Board will consist of three members: Susanne Olauson (Chairman), Martin Roos, and newly elected member Peter Larsson, the company's CFO. More details about the resolutions and the new board member can be found on the company's website. For further information, contact CEO Sebastien Bollue.

Redsense Medical AB höll en extra bolagsstämma den 24 april 2025 där viktiga beslut fattades med nödvändig majoritet. På grund av oförutsedda händelser tidigare under året saknade bolaget en beslutsför styrelse, vilket ledde till att denna stämma kallades. Valberedningen planerar att snart presentera ett förslag på en ny permanent styrelse inför årsstämman i slutet av maj 2025. Vid den extra stämman beslutades det att styrelsen ska bestå av tre ledamöter utan suppleanter fram till nästa årsstämma. Peter Larsson, bolagets CFO, valdes in som ny styrelseledamot, vilket innebär att styrelsen nu består av Susanne Olausson, Martin Roos och Peter Larsson. För mer information hänvisas till bolagets hemsida.

Redsense Medical AB (publ) is calling an Extraordinary General Meeting on April 24, 2025, at Grand Hotel Halmstad. Shareholders must be registered by April 14, 2025, and notify their participation by April 16, 2025. Those with nominee-registered shares need to ensure their shares are registered in their own name by April 14, 2025. Shareholders can vote by proxy if unable to attend in person. The agenda includes electing a Chairman, approving the voting list and agenda, and electing a new Director due to the current Board not being quorate. The Nomination Committee proposes Susanne Olauson as Chairman and Peter Larsson as a new Director. All necessary documents will be available on the company's website and at the meeting. Shareholders can request information per the Swedish Companies Act. For more details, contact CEO Sebastien Bollue.

Styrelsen för Redsense Medical AB har beslutat att hålla en extra bolagsstämma den 24 april 2025 i Halmstad. Aktieägare som vill delta måste vara registrerade hos Euroclear Sweden AB senast den 14 april 2025 och anmäla sitt deltagande senast den 16 april 2025. Möjlighet finns att delta genom ombud med fullmakt. På dagordningen finns bland annat val av ordförande för stämman, fastställande av antalet styrelseledamöter och val av ny styrelseledamot, där valberedningen föreslår Peter Larsson som ny ledamot. Handlingar och ytterligare information kommer att finnas tillgängliga på bolagets webbplats och kan begäras av aktieägare. Syftet med den extra stämman är att välja en ny styrelse på grund av oförutsedda händelser tidigare under året.

Redsense is evaluating the potential effects of new global tariffs announced by President Donald Trump on its operations. The company is in communication with customs brokers, U.S. distribution partners, and customers to monitor the situation and coordinate responses. The impact on medical devices is still uncertain, but Redsense is closely observing developments, including discussions by Medtech groups with the White House. CEO Sebastien Bollue stated that they have sufficient product stock in the U.S. to meet customer demand in the short term. Meanwhile, the launch of the Redsense Clamp, planned for Q1 2025, is delayed due to review processes affected by the high workload from MDR implementation. Redsense is actively engaged with the review process and ready to proceed once approval is received. For more information, contact Sebastien Bollue, CEO, at +46 72-171 1264 or sebastien.bollue@redsensemedical.com.

During the period from October to December 2024, Redsense Medical reported net sales of 12,687 kSEK, a significant increase from the previous year's 8,025 kSEK. The operating profit (EBIT) was 5,525 kSEK, and the result after tax was 5,629 kSEK, both showing a substantial improvement from negative figures the previous year. Earnings per share rose to SEK 0.34. Other operating income/loss was 1,771 kSEK. Significant events included the appointment of the nomination committee for the 2025 Annual General Meeting and the decision not to renew the agreement with OTC Markets Group, ending trading on the OTCQX platform in the USA. After the period, Redsense completed the usability testing phase of the Redsense Clamp, announced the passing of Board Member Malin Almgren, and appointed a new CFO along with part-time support functions. CEO Sebastien Bollue highlighted a strong end to 2024 with record sales and a positive full-year result for the first time in the company's history. The company is focusing on improving operations, strengthening partnerships, and enhancing internal processes. Efforts to secure U.S. reimbursement are ongoing, with the HCPCS application under review. The commercial launch of the Redsense Clamp is planned for early 2025. The company is investing in team and operational improvements to support strategic objectives and anticipates growth and expansion in 2025.

Redsense Medical has announced that Peter Larsson will become the new CFO, succeeding Jennie Kardell, who is leaving to pursue other opportunities. Larsson, with over 30 years of experience in financial leadership roles, will join as a part-time CFO consultant. CEO Sebastien Bollue expressed enthusiasm about Larsson's appointment and thanked Kardell for her contributions. Additionally, Redsense will be supported by a Postdoc intern from Karolinska Institute and a master's student from Halmstad University, both working part-time. These new team members will assist in areas such as health economics research, communication, regulatory affairs, supply chain management, quality management, and sustainability. Bollue highlighted the importance of these additions in supporting the company's growth.

Redsense Medical meddelar att Malin Almgren, en engagerad styrelsemedlem sedan maj 2023, hastigt har avlidit. Hon bidrog med värdefulla insikter baserade på sin starka forskningsinriktning. Susanne Olauson, styrelseordförande, uttrycker att Malin kommer att bli ihågkommen för sin lugna närvaro och skarpa intellekt. Styrelsens valberedning kommer att föreslå nya styrelsemedlemmar inför det kommande årsmötet. För mer information kan Susanne Olauson kontaktas.